StockNews.com Begins Coverage on Aspira Women’s Health (NASDAQ:AWH)

Stock analysts at StockNews.com initiated coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a report released on Sunday. The firm set a “hold” rating on the stock.

Separately, Alliance Global Partners reduced their price objective on Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating on the stock in a research report on Wednesday, August 14th.

Aspira Women’s Health Stock Performance

Shares of AWH opened at $0.86 on Friday. The firm has a 50 day simple moving average of $0.84 and a two-hundred day simple moving average of $1.23. Aspira Women’s Health has a one year low of $0.67 and a one year high of $5.65.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aspira Women’s Health stock. Pine Valley Investments Ltd Liability Co bought a new stake in Aspira Women’s Health Inc. (NASDAQ:AWH) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 31,200 shares of the company’s stock, valued at approximately $25,000. Pine Valley Investments Ltd Liability Co owned 0.19% of Aspira Women’s Health as of its most recent SEC filing. Hedge funds and other institutional investors own 12.19% of the company’s stock.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.